A simpler, faster CRISPR
CRISPR technologies can be programmed to target specific sequences of genetic code and to edit DNA at precise locations. This strategy allows research scientists to permanently modify genes in living cells and model organisms to explore gene function in the laboratory, including genes associated with human disease.
“These technologies permit a ribonucleoprotein complex to cleave DNA at a specific sequence that base-pairs with a guide RNA in the complex. Modularity of the nucleic acid/protein complex allows researchers to specify the guide RNA sequence to target nearly any sequence. This greatly improves researchers’ ability to edit DNA,” said Dr. David Marciano, instructor in the Olivier Lichtarge laboratory at Baylor College of Medicine.
“However, this approach presents some challenges, such as constraints on the sequences that can be targeted, the possibility of off-target effects and the requirement of a unique guide RNA for each target gene,” said Dr. Toon Swings, postdoctoral scientist in the Jan Michiels laboratory at VIB-KU Leuven Center for Microbiology.
Having faced CRISPR challenges repeatedly in their research, Marciano, Swings and their colleagues established an international collaboration that led to a simple solution that circumvents all these issues.
“Toon and I had a set of projects in which we had to construct many mutations and guide RNAs for different genes in the bacterium E. coli. We realized we wouldn’t need a new guide RNA for each gene if we just targeted a universal sequence found in gene knockout collections. The sequence we targeted is found in many genetic collections of medically important bacteria and is even in some fruit fly collections,” Marciano said.
The researchers used a library of E. coli clones called the Keio collection. Each clone in this collection has had one gene replaced by a kanamycin resistance gene. The collection was made available in 2006 through an international collaboration between Keio University of Japan and Purdue University in the United States.
“We ended up repurposing this valuable resource by targeting the two FRT sites flanking the collection’s kanamycin cassette. This works out nicely because it gives you two cuts, which is harder to escape,” Swings said.
The simpler, faster approach avoids some technical aspects of CRISPR and makes it available as an off-the-shelf ingredient for genetic engineering. It removes the need to design and clone a guide RNA and simplifies the strategy for constructing a rescue template.
Also, the Keio collection can be found in laboratories across the globe and individual clones are available for a nominal fee from centralized genetic stock centers.
The new work also presents the broad utility of the approach by showing it is possible to target genes that are essential to life, to make a large collection of organisms with different mutations in a single chromosomal gene and to append new sequences onto a gene, all in the gene’s natural context. The method should complement existing techniques for genetic engineering of E. coli.
“Many model organisms, besides E. coli, have collections of gene replacements or insertions that could be targeted by a single guide RNA in a similar manner,” Swings said. “We hope our work provides a broad platform for a variety of genetic engineering approaches.”
“This is a nice example of the power of bacterial genetics. This is where CRISPR was first discovered, and now again, a different bacterial technology may make it even more useful,” said Dr. Olivier Lichtarge, Cullen Chair of Molecular and Human Genetics, and professor of biochemistry and molecular biology and of pharmacology Baylor College of Medicine. Lichtarge also is a member of the Dan L Duncan Comprehensive Cancer Center at Baylor.
“The developed platform based on CRISPR technology will be valuable to many researchers in microbiology allowing them to perform rapid single nucleotide editing of their genes of interest or to generate chromosomal mutant collections, one of the first steps in understanding gene function,” said Dr. Jan Michiels, group leader at VIB-KU Leuven Center for Microbiology and professor of biochemistry and molecular microbiology at the University of Leuven.
Read all the details of this work in the journal Nature Communications.
Other contributors to this work include Benu Atri, Rachel E. Bosserman, Chen Wang, Marlies Leysen, Camille Bonte, Thomas Schalck, Ian Furey, Bram Van den Bergh, Natalie Verstraeten, Peter J. Christie and Christophe Herman. The authors are affiliated with one or more of the following institutions: Baylor College of Medicine, VIB, University of Leuven and McGovern Medical School, Houston.
Financial support was provided by KU Leuven Research Council (PF/10/010, PDM/17/130, C1/17 3E170455), FWO (G047112N, G055517N, G0B2515N) and the VIB. Support also was provided by the National Institutes of Health (R01GM48746, R01GM088653, NIH-GM079656 and NIH-GM066099) and the National Science Foundation (NSF DBI-1356569).
CRISPR is an acronym for Clustered Regularly Interspaced Short Palindromic Repeats.
